MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.41 5.22

Overview

Share price change

24h

Current

Min

1.33

Max

1.44

Key metrics

By Trading Economics

Income

-2.4M

-40M

Sales

6.2M

45M

Profit margin

-90.427

Employees

485

EBITDA

-6M

-38M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+77.61% upside

Dividends

By Dow Jones

Next Earnings

7 May 2026

Market Stats

By TradingEconomics

Market Cap

-175M

381M

Previous open

-3.81

Previous close

1.41

News Sentiment

By Acuity

14%

86%

29 / 349 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Apr 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 Apr 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 Apr 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 Apr 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 Apr 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 Apr 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 Apr 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 Apr 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 Apr 2026, 23:58 UTC

Market Talk
Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 Apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 Apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 Apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 Apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 Apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 Apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 Apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 Apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 Apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 Apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 Apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 Apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 Apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 Apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 Apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 Apr 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 Apr 2026, 17:59 UTC

Market Talk
Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 Apr 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 Apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 Apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 Apr 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

77.61% upside

12 Months Forecast

Average 2.38 USD  77.61%

High 3 USD

Low 1.5 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

2

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

29 / 349 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat